scholarly journals Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies

2016 ◽  
Vol 64 (8) ◽  
pp. 1592-1600 ◽  
Author(s):  
Shoroq M. Altawalbeh ◽  
Carolyn T. Thorpe ◽  
Janice C. Zgibor ◽  
Sandra Kane-Gill ◽  
Yihuang Kang ◽  
...  
Keyword(s):  
Older Adults ◽  
Persistent Asthma ◽  
Beta Agonists ◽  
Long Acting

scholarly journals The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Donald P. Tashkin ◽  
Jill A. Ohar ◽  
Arkady Koltun ◽  
Richard Allan ◽  
Jonathan K. Ward
Keyword(s):  
Fluticasone Propionate ◽  
Inhaled Corticosteroids ◽  
Persistent Asthma ◽  
The United States ◽  
Fixed Dose ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Beta Agonists ◽  
Treatment Plans ◽  
Long Acting

Both asthma and chronic obstructive pulmonary disease (COPD) are inflammatory chronic respiratory conditions with high rates of morbidity and mortality worldwide. The objectives of this review are to briefly describe the pathophysiology and epidemiology of asthma and COPD, discuss guideline recommendations for uncontrolled disease, and review a new generic option for the treatment of asthma and COPD. Although mild forms of these diseases may be controlled with as-needed pharmacotherapy, uncontrolled or persistent asthma and moderate or severe COPD uncontrolled by bronchodilators with elevated eosinophilia or frequent exacerbations may require intervention with combination therapy with inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), according to international guidelines. Fixed-dose combinations of ICS/LABA are commonly prescribed for both conditions, with fluticasone propionate (FP) and salmeterol forming a cornerstone of many treatment plans. An oral inhalation powder containing the combination of FP and salmeterol has been available as Advair Diskus® in the United States for almost 20 years, and the first and only substitutable generic version of this product has recently been approved for use: Wixela™ Inhub™. Bioequivalence of Wixela Inhub and Advair Diskus has been established. Furthermore, the Inhub inhaler was shown to be robust and easy to use, suggesting that Wixela Inhub may provide an alternative option to Advair Diskus for patients with asthma or COPD requiring intervention with an ICS/LABA.

scholarly journals Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma

PLoS ONE ◽  
2011 ◽  
Vol 6 (2) ◽  
pp. e17242 ◽  
Author(s):  
Lisa Hartling ◽  
Kenneth Bond ◽  
Ben Vandermeer ◽  
Jennifer Seida ◽  
Donna M. Dryden ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inhaled Corticosteroids ◽  
Persistent Asthma ◽  
Risk Of Bias ◽  
Beta Agonists ◽  
Long Acting

scholarly journals Comparative study of inhaled steroids versus inhaled steroids plus long acting beta agonists in childhood asthma: a randomized controlled study

2020 ◽  
Vol 8 (6) ◽  
pp. 2162
Author(s):  
Wasim A. Wani ◽  
Sheeraz A. Dar ◽  
Mudasir Nazir ◽  
Ikhlas Ahmad
Keyword(s):  
Airflow Obstruction ◽  
Persistent Asthma ◽  
Controlled Study ◽  
P Value ◽  
Inhaled Steroids ◽  
Randomized Controlled ◽  
Beta Agonists ◽  
Chronic Inflammatory Condition ◽  
Significant Difference ◽  
Long Acting

Background: Asthma is a chronic inflammatory condition of lung airways resulting in episodic airflow obstruction causing considerable morbidity in paediatric population. The main objective of the study was to find out whether addition of long acting beta agonists to steroids provides better asthma control.Methods: This randomized controlled trial study was performed in children aged 6-15 years of age, with clinically stable and moderate persistent asthma.Results: The findings of this study indicate SABA use in Budesonide/formoterol group patients was significantly less compared to budesonide group patients (1.5±1.1 v/s 2.13±0.9, p-value 0.01). Both groups experienced decrease in night time symptoms and acute exacerbations however there was no significant difference between the two groups in these variables.Conclusions: This study showed addition of LABA to inhaled steroids in moderate persistent asthma provided better asthma control and LABA is mainly recommended to be used as add-on therapy for patients whose asthma is not controlled on low to high doses of inhaled corticosteroids.

Sign in / Sign up

Export Citation Format

Share Document